Search - tctmd.com

Displaying 661 - 680 of 795

Presentation TCT 2013

Comparison Of Long-term Outcomes With Everolimus-Eluting- and Sirolimus-Eluting Stents In Small Coronary Artery Disease

Presenter: Hironori Kitabata, Joshua Loh, Gabriel Sardi, Salem Badr, Danny Dvir, Israel Barbash, Rebecca Torguson, Kenneth Kent, Lowell Satler, William Suddath, Augusto Pichard, Ron Waksman

January 31, 2013

Presentation TCT 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presenter: Renato Valenti, Angela Migliorini, Guido Parodi, Ruben Vergara, Nazario Carrabba, Emilio Vincenzo Dovellini, David Antoniucci

January 31, 2013

Presentation TCT 2013

Biodegradable-Polymer Biolimus Eluting Stents Show Better Antiproliferative Efficacy And Vascular Healing Pattern Than Permanent-Polymer Paclitaxel Eluting Stents in a Preclinic...

Presenter: Armando P?rez de Prado, Claudia P?rez-Mart?nez, Alejandro Diego, Jos? Manuel Gonzalo-Orden, Carlos Cuellas, Marta Regueiro, Beatriz Mart?nez-Fern?ndez, Jose M Ajenjo, Maria J Garcia-Iglesias, Felipe Fern?ndez-V?zquez

January 31, 2013

Presentation TCT 2013

Below-Knee Drug Eluting Stents Have Improved Patency, and Symptoms Compared to Bare Metal Stents: a meta-analysis

Presenter: Alexandre Benjo, Francisco Macedo, Emad Aziz, Francisco Nascimento, Fahad Javed, Eyal Herzog, Tyrone Collins, Christopher White

January 31, 2013

Presentation TCT 2013

Abluminal- Only Coating Everolimus Eluting Coronary Stent Provides an Anti-inflammatory Vascular Effect Compared to Bare Metal Stents in the Familial Hypercholesterolemic Swine

Presenter: Armando Tellez, Elina Donskoy, Natalia Sushkova, Paul Seifert, Taylor Palmieri, William Rate, Samantha Stone, Michael Eppihimer, Greg Kaluza, Barbara Huibregtse, Keith Dawkins, Juan Granada

January 31, 2013

Presentation

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

Presenter: K. W. Park

December 25, 2012

Presentation

Self-Expanding vs. Balloon-Expandable Stents in AMI: APPOSITION II

Presenter: R.J. van Geuns

December 16, 2012

Presentation

Zotarolimus-Eluting Peripheral Stents for the Treatment of ED in Subjects with Suboptimal Response to Phosphodiesterase-5 Inhibitors

Presenter: J.H. Rogers

November 25, 2012

Presentation

BELLO: Paclitaxel Drug-Eluting Balloons vs. Paclitaxel-Eluting Stents in Small Coronary Vessels

Presenter: A. Latib

November 13, 2012

Presentation TCT 2012

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

Presenter: Adam de Belder

October 26, 2012

Presentation TCT 2012

Coronary Complication Spectacle: From Air Emboli to Dislodged Stents to No Reflow, Perforations, and More

Presenter: John Douglas Jr

October 26, 2012

Presentation TCT 2012

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

Presenter: Antonio Colombo

October 26, 2012

Presentation TCT 2012

ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of Limus-Eluting Coronary Stents

Presenter: Robert Byrne

October 26, 2012

Presentation TCT 2012

Will Polymer-Free DES Be Safer Than Bare Metal Stents?

Presenter: Philip Urban

October 25, 2012

Presentation TCT 2012

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

Presenter: Clemens von Birgelen

October 25, 2012

Presentation TCT 2012

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Ken Kozuma

October 25, 2012

Presentation TCT 2012

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

Presenter: Francesco Burzotta

October 25, 2012

Presentation TCT 2012

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

Presenter: Dean Kereiakes

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Patrick Serruys

October 25, 2012

Advertisement

Comparison Of Long-term Outcomes With Everolimus-Eluting- and Sirolimus-Eluting Stents In Small Coronary Artery Disease

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Biodegradable-Polymer Biolimus Eluting Stents Show Better Antiproliferative Efficacy And Vascular Healing Pattern Than Permanent-Polymer Paclitaxel Eluting Stents in a Preclinic...

Below-Knee Drug Eluting Stents Have Improved Patency, and Symptoms Compared to Bare Metal Stents: a meta-analysis

Abluminal- Only Coating Everolimus Eluting Coronary Stent Provides an Anti-inflammatory Vascular Effect Compared to Bare Metal Stents in the Familial Hypercholesterolemic Swine

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

Self-Expanding vs. Balloon-Expandable Stents in AMI: APPOSITION II

Zotarolimus-Eluting Peripheral Stents for the Treatment of ED in Subjects with Suboptimal Response to Phosphodiesterase-5 Inhibitors

BELLO: Paclitaxel Drug-Eluting Balloons vs. Paclitaxel-Eluting Stents in Small Coronary Vessels

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

Coronary Complication Spectacle: From Air Emboli to Dislodged Stents to No Reflow, Perforations, and More

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of Limus-Eluting Coronary Stents

Will Polymer-Free DES Be Safer Than Bare Metal Stents?

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content